Introduction {#S1}
============

Dehydrated Hereditary Stomatocytosis, (DHS, Xerocytosis, MIM \#194380) is a dominantly inherited pleiotropic syndromecharacterized by increased permeability of red blood cell (RBC) membranes to cations (for review see Delaunay J (2004))^[@R1]^. It is typically associated with silent to mild hemolysis, pseudohyperkalaemia (*ie* loss of K^+^ from red cells on storage at room temperature), and perinatal edema^[@R2]^. A minor proportion of the red cells appear as stomatocytes on blood films. As is frequently observed in chronic haemolytic diseases, complications such as splenomegaly, resulting from increased red cell trapping in the spleen, and cholelithiasis, resulting from elevated bilirubin levels, may occur. For unknown reasons, the course of DHS is frequently associated with iron overload that may lead to hepatosiderosis^[@R3]^.

Two genetic loci have been associated with DHS. Linkage to locus 16q23-qter was demonstrated in 1998^[@R4]^which we further refined to a 11.5 cM interval based on information available on a large 3-generation pedigree^[@R5]^, an interval confirmed in another large Canadian kindred^[@R6]^. Recently, two missense mutations at the FAM38A gene lying in this interval and encoding the PIEZO1 protein (M2225R and R2456H) were associated to DHS in two large North-American pedigrees^[@R7]^.A second locus for DHS was identified on chromosome 2q35q36 for at least one family^[@R8],[@R9]^. Very recently the Iolascon'sgroup identified two heterozygous missense gain-of-function mutations at a single residue (R375) in the *ABCB6* gene causing familial pseudohyperkalemia, a related disorder, in three multigenerational families^[@R10]^. ABCB6 is a porphyrin transporter present in erythrocytes membranes. Whether ABCB6 and PIEZO1 act through a shared pathway is unknown.

PIEZOs are newly identified mechanically activated (MA)cation channels. These ion channels are proposed homotetramers, with each subunit encompassing 30 - 40 transmembrane domains. They are expressed in many cell types including human erythroid progenitor cells^[@R7],[@R11],[@R12]^. Some insights into the roles of PIEZO1 have been obtained recently by knock-down experiments in mammalian epithelial cells from kidney and lung, and in lung cancer cells^[@R13],[@R14]^. In the context of kidney epithelial cells, PIEZO1 is proposed to act as a sensor of cell tension. McHugh et al. demonstrated that PIEZO1 inactivation promotes cell migration of normal lung epithelial cells, and leads to a switch towards beta-integrin independent amoeboid migration of small lung cancer cells. Evidence for PIEZO function *in vivo*is still limited. InDrosophila, Piezo is required for mechanical nociception^[@R15]^, and as mentioned above, twohuman *PIEZO1*mutations are associated with DHS patients described by Zacharykanski et al. However, the mechanism by which these mutations alter channel properties and in turn cause the observed phenotype is yet to be elucidated.

Here, we identify three additional missense mutations and one recurrent duplication mutation in *PIEZO1* of DHS patients. Functional characterization of recombinant PIEZO1 channels containing any one of these mutations indicates that they are all gain-of-function mutations that could cause a net increase in ion flux leading to DHS.

Results {#S2}
=======

Mutation detection {#S3}
------------------

Our genetic analysis had begun when the gene causing DHS was not yet known. We first performed a whole exome sequencing analysis using two distant affected subjects of our large previously described pedigree^[@R5]^ ([Fig. 1](#F1){ref-type="fig"}). Predicted functional coding and unique variants were found at 5 genes contained in the linkage interval ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}and [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). However, only two missense variants were not shared by the unaffected subject, the *CDT1* and *FAM38A* -- *PIEZO*1 genes. While CDT1 (Chromatin licensing and DNA replication factor 1) belongs to a family of DNA replication proteins and is essential for DNA replication, PIEZO1 appeared as a more attractive candidate because of its recent identification as mechanically activated ion channels involved in mammalian mechanotransduction^[@R12]^.

Genotyping of the *PIEZO1* p.Ala2020Thr (A2020T) variant, identified by exome sequencing, in 14 affected and 5 unaffected members of the Family 1 showed a complete co-segregation with the disease. Bioinformaticsoftwares (SIFT, Polyphen 2) showed a high likelihood of pathogenicity score ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}). We then performed a systematic screening of the entire coding sequence of *PIEZO1* gene in a series of two other kindreds and 11 unrelated DHS cases. Index cases were referred to our centre for investigation of chronic Coombs testnegative hemolysis, with few symptoms for most of them. DHS was diagnosed by ektacytometry, andshowed the typical dehydrated profile in each case. As expected, the electrophoretic analysis of RBC membrane protein was normal. Other biological and clinical findings were in agreement with the DHS diagnosis([Table 1](#T1){ref-type="table"}). Three additional mutations were found in 10 subjects ([Table 1](#T1){ref-type="table"}): two missense mutations, p.Arg1358Pro (R1358P) and p.Thr2127Met (T2127M), and a duplication of six nucleotides GGAGCT at the very end of exon 51, about 70 nucleotides before the stop codon ([Fig. 1](#F1){ref-type="fig"} and [Supplementary Fig. S2](#SD1){ref-type="supplementary-material"}). This duplication (c. 7479_7484dup) occurs in a region of low complexity and rich in Leucine (L) and Glutamate (E) codons. The resulting staggered in-frame duplication of Leucine 2495 and Glutamate 2496 (p.Leu2495_Glu2496dup) will be addressed as E2496ELE.

We observed that E2496ELE was recurrently found in 8 unrelated index cases ([Table 1](#T1){ref-type="table"}). Haplotype analysis using SNPs at the *PIEZO1* gene showed that this in-frame duplication was carried by at least 4 different haplotypes, thus excluding an ancestral allele ([SupplementaryTable S3](#SD1){ref-type="supplementary-material"}). A majority of available bioinformaticsoftwares could not predict its pathogenicity, but Mutation Taster considered it as possibly polymorphic. However, it was absent from the 1000 Genomes, Exome Variant Server, or dbSNP v135 databases. The four mutations were found in PIEZO1 motifswith a high level of conservation amongst vertebrates ([Fig. 1a](#F1){ref-type="fig"}).

We further assessed the frequency of E2496ELE in 600 healthy French controls and found it twice amongst 1200 alleles (MAF = 0.0017), contrasting with a very highlysignificant proportion of mutated alleles in our DHS series (8/22, MAF=0.36, p\<10^−76^). Of note, one of the two positive healthy individuals was considered to have hyperkalaemia in one of his blood tests, with no additional information. Another argument for pathogenicity of this recurrent variant was provided by its co-segregation with DHS diagnosis in families2 and 3 ([Fig. 1b](#F1){ref-type="fig"}). In these two families, each positive subject had both pseudohyperkalaemia and abnormal haematologic parameters. The penetrance of the condition could therefore be considered as 100% in the tested individuals. No obvious/simple genotype-phenotype relationship appear from our data; however, we noticed that this restricted sample of 8 index cases bearing the E2496ELE mutationhad a tendency for lower age at diagnosis (20.5 vs 60.6 years) and a more severe haematological phenotype compared to the 3 index cases carrying a missense mutation ([Table 2](#T2){ref-type="table"}). This observation needs to be confirmed with larger number of subjects.Overall, four different mutations lying in highly conserved C-terminal regions of the PIEZO1 protein ([Fig. 2](#F2){ref-type="fig"}) were found in 11 unrelated familial and sporadic DHS cases with strong arguments of pathogenicity for each of them.

Electrophysiological studies of DHS mutations in hPIEZO1 channels {#S4}
-----------------------------------------------------------------

We then set out to determine if these mutations alter PIEZO1 channel activity. We introduced the four mutations identified from our study (R1358P, A2020T, T2127M and E2496ELE) and the two previously published (M2225R and R2456H)DHS-associated mutations^[@R7]^in *hPIEZO1* full length cDNA. We transfected HEK293T cells with wild-type (WT) or mutant *hPIEZO1*and analyzed channel activity via whole-cell patch clamp configuration. Mechanically activated (MA) inward currents were recorded by applying mechanical force on to the cell surface using a glass probe^[@R12]^ ([Fig.3a](#F3){ref-type="fig"}). In cells expressing WT hPIEZO1 such stimulation gives rise to rapid transient increase in current.

Sensitivity of achannel to mechanical stimulation, which can also be expressed as the distance of the mechanical stimulus, can be estimated by measuring 'threshold' values for each cell. We measure this by subtracting the distance at which the probe first touches the cell surface from the minimal distance at which mechanically activated currents are evoked.Threshold is therefore merely the distance of indentation, after making cell contact, required to activate the channel. We observed no apparent differences in threshold values for any of the hPIEZO1 mutants relative to WT hPIEZO1 suggesting that the DHS mutations do not alter the channel's sensitivity to mechanical stimulation ([Table 3](#T3){ref-type="table"}).

Similar to WT hPIEZO1, all the mutants had a linear current-voltage correlation with a reversal potential close to 0 mV ([Supplementary Fig. S3](#SD1){ref-type="supplementary-material"}). At −80 mV, the maximum current (I~max~) recorded from cells expressing mutant hPIEZO1 channels was found to be similar to that of WT hPIEZO1 ([Table 3](#T3){ref-type="table"}). A potential exception to this was M2225R-induced currents, which showed overall larger I~max~ currents. However, the average was not significantly different compared to WT. In addition, peak currents depend on expression levels in HEK293T cells, and might not represent endogenous expression.

All WT and mutant hPIEZO1 MA inactivation currents could be fit with a mono-exponential function.Remarkably, we observed that all mutations caused considerable increase in the inactivation time constantrelative to WT channel kinetics ([Fig.3b](#F3){ref-type="fig"}). The R2456H mutation had the maximum impact with a 2.6 fold slower time constant, while the remaining5 mutations inactivate with 1.3 to 1.7 fold slower kinetics ([Fig. 3c](#F3){ref-type="fig"} and [Table 3](#T3){ref-type="table"}).Therefore, all 6 mutations can be defined as gain-of-function, as they would give rise to an increased channel activity in response to a given mechanical stimulus.

Discussion {#S5}
==========

We present a comprehensive analysis of DHS-causing *PIEZO1* mutations. Four novel*PIEZO1* mutations were identified in 11 out of 14 index cases, demonstrating that this gene playsa major role in DHS.DHS is a difficult diagnosis because of a highly variable clinical expression, ranging from the absence of clinical symptoms to lethal perinatal edema. Other features of DHS include severe iron overload leading to hepatic transplantation, or life threatening thromboembolic disease after splenectomy. But the most frequent DHS condition ismoderately symptomatic hemolysis. The only biological test for DHSisektacytometry, which is available in a very limited number of laboratories. The disease may be overlooked for years or decades and is sometimes confused with spherocytosis. Our data, including the presence of a recurrent mutation, render a genetic diagnosis possible.

PIEZO1is a largehomotetramericmechanosensitive ion channelwith each subunit containing 2521 amino acids and predicted to encompassno less than 30 transmembrane domains^[@R11]^. However, PIEZOs do not share homology with any known ion channels or proteins. Interestingly, all six DHS-associated PIEZO1 mutations are located in the second half of the coding sequence. Indeed, apart from R1358P, all are in the C-terminal 1/5^th^ of the protein, albeit distributed across several exons in the gene. It is difficult to conclude too much from this information, as we know virtually nothing about the topology of PIEZO1, or the role of different PIEZO regions in channel function.However, our electrophysiological studies implicate the C-terminal region in regulating gating kinetics.

Human *PIEZO1* is a very polymorphic gene. As an example, many coding variants of *PIEZO1* are present in the 1000 genomes database, including variants predicted as deleterious. Interestingly, the distribution of these variants tends to cluster to the N-terminal end of the protein, unlike DHS mutations ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}), suggesting an increasing selective pressure from the N-terminal to the C-terminal end of the protein. One surprising finding is the recurrence of the E2496ELE mutation, observed in 8 out of the 11 DHS PIEZO1-related cases. It was also found twice in 1200 healthy controls of French origin. We had no access to the medical record of these two *a priori* asymptomatic subjects, but one of these two heterozygous carriers had hyperkalaemia. As mentioned above, this in-frame insertion can neither be explained by a founder effect nor could be considered as a polymorphism taking into account its rarity in the general population, its associated clear phenotype and its electrophysiological consequences. The 6-nucleotide inserted sequence "GGAGCT" represents a short intragenic in-frame insertion, embedded in a low complexity surrounding sequence between positions 2491 and 2499. Slippage mutagenesis, leading to the addition or removal of one copy of a short tandem repeat is probably responsible for this recurrence. In the human genome, microdeletions and microinsertions ofgreater than 1 to less than 20 nt were found to be strongly associated with surrounding short tandem repeats, similar to the sequence surrounding this duplication^[@R16]^.

Characterization of kinetic properties of mutant PIEZO1 channels showed a striking effect: allsixDHS causing mutationsresulted in a similar slowing of inactivation kinetics. We propose that these mutations could affect the inactivation mechanism by either destabilizing the inactivated state orstabilize the channel in the open state thereby biasing the open to inactivated state equilibrium towards open, resulting in an increased Na^+^ and Ca^2+^ ion influx. RBCs are unique in that they circulate in the vascular system for 120 days and undergo constant mechanical stress, specifically through the capillaries and splenic cords. Stabilization of the open conformationof PIEZO1 channels in RBCs could also alter the transition between closed and open states of the channel leading to higher open probability compared to WT channels. This shift in kinetics could potentially also cause a slight increase in basal channel activity (independent of mechanical stimulation) which may also contribute to the DHS phenotype.

Detailed kinetic analysis of these channels in the future should tell us more about the gating mechanism and how these mutations in PIEZO1 could lead to erythroid dysfunction.Our analysis here was restricted to heterologously expressed PIEZO1 mutants. Recording of mechanically activated currents from control and affected RBCs in the future could more directly link PIEZO1-dependent current characteristics and pathophysiology of DHS.

It is possible that increased PIEZO1 activity could directly contribute to RBC dehydration observed in DHS patients. Human RBCs have a resting membrane potential of about −10 mV, and one possibility is that the gain of function mutations cause increase in influx of Na^+^ and efflux of K^+^through PIEZO1 channels. Indirect mechanisms could also account for this phenotype. For example, PIEZO1-mediated rise in intracellular Ca^2+^ concentration could induce K^+^ efflux by the activation of Ca^2+^ activated K^+^ channels, the Gardos channel. Gardos channels have been shown to play a vital role in physiological and pathological states of erythrocytes. Additionally, it has been shown that Gardos channel activation causes a reduction in erythrocyte cell volume^[@R17],[@R18]^.

Multiple cell types along with erythroid progenitor cells expressPIEZO1^[@R7]^. The specifichaematologic phenotype of DHS patients due to gain-of-function PIEZO1 mutants is therefore surprising. It is, however, important to note that DHS is a mostly tolerated disorder, and even the RBC phenotype is relatively subtle - as reflected by the modest changes of RBC constants such as mean cell volumeand mean cell hemoglobin concentrationor the weak (5-15%) number of stomatocytes^[@R1],[@R19]^. Therefore, variations in minor modulating factors could impact which cell types show phenotypes in DHS patients. For example, RBCs might be more sensitive to increased cation flux compared to other cell types, or PIEZO1channels expressed in RBCs might bemodulated in a way that amplifies the consequences of the *PIEZO1* mutations. Another intriguing possibility is that RBC plasma membranes experience more mechanical stress compared to other cells due to their unique membrane properties and constant movement during blood circulation. It is also possible that other cell types and tissues are affected in DHS patients, but these have remained unknown or unexplained due to these modulating factors and the possible subtleness of phenotype. Perinatal edema that is inconstantly observed in DHS patients is such an example.*PIEZO1* is expressed in endothelial cells (unpublished data) and this phenotype could be the consequence of a leak out of the vascular compartment at a specific development stage. PIEZO1 has been implicated in cell-cell and cell-matrix interactions^[@R20]^. In both PIEZO1 knockdown experiments^[@R13],[@R14]^,the mechanosensitivity and gating properties of the protein were not assessed, but the influence of PIEZO1 on cell migration/invasion and extrusion was described.

The function of a mechanosensitive PIEZO1 channel in normal RBCs remains speculative. Erythrocytes are highly deformable cells, a property that allows them to pass though narrow capillaries of the microvasculature^[@R21]^. Mechanosensory feedback mechanisms could allow the cell to respond to its changing mechanical environment, possibly by regulating its volume and morphology. In this respect it is interesting to comment onOverhydrated Hereditary Stomatocytosis, another genetic disease that like DHS is associated with an imbalance in erythrocyte cation gradients. This disease is associated with mutations in Rhesus associated glycoprotein (RhAG), and is characterized by a dramatic reduction of stomatin from erythrocyte membranes^[@R1],[@R22],[@R23]^. Strikingly,stomatin family members from mouse and worm have been shown to be required for mechanotransduction in sensory neurons^[@R24]-[@R26]^. This tantalizing coincidence raises the possibility that the various genetic conditions that cause stomatocytosis are caused by disrupted mechanotransduction, and that perhaps PIEZOs and stomatinfamily members function in the same pathway. Yet another clue towards a role for mechanotransduction in erythrocytes comes from sickle cell disease, arguably the best known erythrocyte disorder. In sickle RBCs, mutant hemoglobin molecules form large polymers under low oxygen conditions, which cause the deformation of the erythrocyte. This deformation coincides with the development of a cationic membrane current, termed pSickle, and subsequent erythrocyte dehydration^[@R17]^. Notably pSickle is blocked by a blocker of stretch-activated currents, the tarantula toxin Gsmtx4, which is also known to block PIEZO1^[@R27]-[@R29]^. Future studies will explore the relationship between PIEZO1 and pSickle.

In conclusion, we identifyfournew PIEZO1 mutations in DHS patients, demonstratingthat PIEZO1 isa major determinant of DHS. Wealsopresent the first functionalanalysis of DHS-causing PIEZO1 mutations. Our studiesprovide a substantial step towards understanding physiopathology of DHS. Our findings will also be useful to establish DHS genotype/phenotype relationship and to refine the classification of RBCcation leak disorders on a molecular basis.

During the final revision of this manuscript, two related papers were published which also show that DHS mutations in PIEZO1 alter channel activity^[@R30],[@R31]^.

Methods {#S6}
=======

Patients {#S7}
--------

Our study focused on three families and 11 independent index-cases with a typical DHS clinical and biological phenotype. Patients were from all regions of France, and were diagnosed through specialized consultation by a haematologist or a clinical geneticist. Some of the patients have been published elsewhere: Family 1, which was described by us and others (Family VA in Grootenboer et al, 2000 andBeaurain et al, 2007)^[@R2],[@R5]^, presented with mild, uncomplicated haematological signs of the disease, pseudohyperkalaemia, and no history of perinatal edema. In Family 2 (Family VE in Grootenboer et al, 2000) patients were affected by a mild to moderate haemolysis and anemia, by a recurrence of perinatal edema (3 affected cases), and varying recurrence of pseudohyperkalaemia. Case 4^[@R3]^ and Family 3^[@R32],[@R33]^ were case reports, these patients expressed a moderate form of anemia and hemolysis without initial evidence of perinatal edema or pseudohyperkalaemia. In these last three cases, diagnosis of DHS was done late after the onset of haematologic manifestations. The other cases were referred to the Haematology Department of the Hospital Kremlin-Bicêtre and their characteristics are summarized in [Table 1](#T1){ref-type="table"}.

Informed consents for genetic analysis were obtained for all patients, according to local institutional ethical board,Hôpital Européen Georges Pompidou Ethicalcomitee. The research was conducted in the HôpitalEuropéen Georges Pompidou Genetics Department or the Haematology Department of Kremlin-Bicêtre University Hospital in Paris, France, and the Scripps Research Institute in San Diego, California.

Haematological tests {#S8}
--------------------

Blood electrolytes were measured in each center. Red blood cell studies were performed in the same laboratory: cell counts and red cell constants were measured using an ADVIA 2120 (Siemens) instrument, blood smears were observed after May-Grünwald-Giemsastaining using standard methods, red cells membrane properties were assessed using osmolar gradient (ranging from 80 to 500 mosmol/kg) ektacytometry using a Techniconektacytometer and erythrocyte membrane proteins analyzed by SDS-PAGE as previously described^[@R1],[@R34],[@R35]^.

Molecular genetics analysis and targeted exome sequencing {#S9}
---------------------------------------------------------

Genomic DNA was extracted from EDTA blood samples using the QIAamp Midi Kit blood DNA extraction kit (Quiagen). Quality of the DNA was evaluated using nanodrop 2000 spectrophotometer (Thermo Scientific).

Library preparation, capture, sequencing, and variants detection and annotation, were performed by IntegraGen, Evry, France. Exons of genomic DNA samples were captured using Agilent in-solution enrichment methodology with their biotinylated oligonucleotides probes library, followed by paired-end 75 bp massively parallel sequencing on IlluminaHiSeq 2000. For detailed explanations of the process, see Gnirke publication in Nature Biotechnology^[@R36]^. Sequence capture, enrichment and elution were performed according to manufacturer's instruction and protocols (Human All exon kit V3, 50Mb, Agilent) without modification. Briefly, 3 μg of each genomic DNA were fragmented by sonication and purified to yield fragments of 150-200 bp. Paired-end adaptor oligonucleotides from Illumina were ligated on repaired A-tailed fragments, then purified and enriched by 6 PCR cycles. 600 ng of these purified libraries were hybridized to the SureSelectoligo probe capture library during 72 hrs. After hybridization, washing, and elution, the eluted fraction was PCR-amplified with 11 cycles, purified and quantified by qPCR to obtain sufficient DNA template for downstream applications. Each eluted-enriched DNA sample was then sequenced on an IlluminaHiSeq 2000 as paired-end 75b reads. Image analysis and base calling were performed using Illumina Real Time Analysis (RTA) Pipeline version 1.14 with default parameters.

Bioinformatics analysis of *PIEZO1* for exome study {#S10}
---------------------------------------------------

The bioinformatics analysis of deep sequencing data was based on the Illumina pipeline (CASAVA 1.8). CASAVA performs alignment of the reads to the human reference genome (hg19) with the alignment algorithm ELANDv2 (performs multiseed and gapped alignments), then calls the SNPs based on the allele calls and read depth, and detects variants (SNPs &Indels). Only the positions included in the bait coordinates were conserved. Genetic variations annotation was performed using IntegraGen in-house pipeline, which consists in gene annotation (RefSeq), detection of known polymorphisms (dbSNP v132, 1000 Genomes) followed by a mutation characterization (exonic, intronic, silent, nonsense, etc.). For each position, the exomic frequencies (Homo & Heterozygous) were determined from the IntegraGen Exome database, and the exome results provided by HapMap. Results were provided per sample and family upon tabulated text files, including coverage/depth statistical analysis per exome and per target.

Genomic sequences of all 51exons of *PIEZO1* gene were amplified by PCR using either Red'y star reaction mix (Eurogentec) or Jumpstart reaction mix (Sigma). Twenty different primer pairs amplifying one or more exons each, targeting the unique reference transcript sequence of the gene (NM_001142864.2) were used. Sequencing reactions of the PCR products were performed using the Big Dye Terminator sequencing kit v3.3 (Life Technologies, Carlsbad, California, USA). Twenty-five additional primers were used to obtain the complete coding sequence of the gene from both strands. Sequencing products were migrated on an ABI prism 3730 sequencer (Life Technologies, Carlsbad, California, USA) and analyzed using the Sequencher 5.0 software (Genecodes, Ann Arbor, Michigan, USA).

Sequencing of *PIEZO* exon 51, for population frequency estimation of E2496ELE, was performed in 1200 control alleles from a French healthy controls cohort. Primer pairs and PCR conditions are available upon request.

Sequence alignment and analysis were performed using Sequencher software 5.0 (Gencodes, Ann Arbor, Michigan, USA). Sequence variations were analyzed using Alamut (Interactive Biosoftware, Rouen, France), and predicted pathogenicity of variants was assessed using Polyphen 2, SIFT, and Mutation Taster online tools. Frequency of variants in published populations were assessed in 1000 genomes, Exome Variant Server, and dbSNP databases. Human to other vertebrates protein alignments of PIEZO1 were performed using CLUSTAL Omega.

All web tools addresses are listed in the [Supplementary Table S4](#SD1){ref-type="supplementary-material"}.

Cloning and tissue culture {#S11}
--------------------------

Halo tagged *hPIEZO1* was purchased from KazusaDNA Research Institute. This clone differs from the NCBI sequence with coding differences at I83T, V250A, V394L and R407G and non-coding differences at codons 1338, 1846, 2190, 2214 and 2353.We first confirmed the functionality of the clone through electrophysiological experiments. The cDNA was thencloned into pIRES2-eGFP expression vector and the DHS mutations were generated either by overlapping PCR mutagenesis or by using Agilent's QuikChange II XL Site Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. All clones were verified by full length DNA sequencing. Human embryonic kidney 293T (HEK293T) cells were grown in Dulbecco's Modified Eagle Medium containing 4.5 mg.ml^−1^ glucose, 10% fetal bovine serum, 50 U.ml^−1^ penicillin and 50 mg.ml^−1^ streptomycin. Cells were plated onto poly-lysine-coated 12-mm round glass coverslips placed in 24-well plates and transfected using lipofectamine 2000 (Invitrogen) according to the manufacturer's instruction. 600 ng.ml^−1^ of plasmid DNA was transfected and GFP positive cells were recorded from, 12-48 h post transfection.

Electrophysiology and mechanical stimulation {#S12}
--------------------------------------------

Patch-clamp experiments were performed in standard whole-cell recordings using an Axopatch 200B amplifier (Axon Instruments). Patch pipettes had a resistance of 1.5-3 MΩ when filled with intracellular solution consisting of (in mM) 133 CsCl, 5 EGTA, 1 CaCl~2~, 1 MgCl~2~, 10 HEPES, 4 MgATP and 0.4 Na~2~GTP (pH adjusted to 7.3 with CsOH). The extracellular solution consisted of (in mM) 130 NaCl, 3 KCl, 1 MgCl~2~, 2.5 CaCl~2~, 10 HEPES and 10 glucose (pH adjusted to 7.3 with NaOH). All experiments were done at room temperature. Currents were sampled at 20 kHz and filtered at 2 kHz. Voltages were not corrected for a liquid junction potential. Leak currents before mechanical stimulations were subtracted off-line from the current traces.

Mechanical stimulation was achieved using a fire-polished glass pipette (tip diameter 3--4 μm) positioned at an angle of 80° to the recording cell. Downward movement of the probe towards the cell was driven by a Clampex controlled piezo-electric crystal microstage (E625 LVPZT Controller/Amplifier; PhysikInstrumente). The probe had a velocity of 1 μm.ms^−1^ during the ramp segment of the command for forward motion and the stimulus was applied for 150 ms.To assess the mechanical sensitivity of a cell, the probe is first placed as close to the cell as possible (this distance could vary from cell to cell). Then,a series of mechanical steps in 1 μm increments was applied every 10s, which allowed full recovery of mechanosensitive currents. Threshold was calculated by subtracting the distance at which the probe first touches the cell surface from the minimal distance at which mechanically activated currents are evoked.Mechanically activated inward currents were recorded at a holding potential of −80 mV. For I--V relationship recordings, voltage steps were applied 0.7 s before the mechanical stimulation from a holding potential of −60 mV.

Statistical analysis {#S13}
--------------------

Frequency comparisons of variants were done using Fisher exact test. Clinical and haematological quantitative variables comparisons between subsets of patients were done using Student's t-tests. Channel kinetic properties between WT and mutant PIEZO1 were compared using Student's t-test.
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![Mutation screening results in *PIEZO1* amongst patients and relatives\
(**a**) Graphical representation of the 51 exons of human PIEZO1 gene, with evolutionary proteic conservation analysis of the mutants surrounding regions amongst vertebrates. Blue boxes: exons. Red lollipops: location of the identified mutations. Red boxes in aligned sequences: Amino acid residues concerned by the mutations. (**b**) Pedigrees of the three French DHS families with corresponding mutations. Black arrowheads: index-cases; asterisks: affected patients selected for exome sequencing; + and −, respectively: presence or absence of the described mutation.](nihms-470226-f0001){#F1}

![Hydrophobicity plot of human PIEZO1 and position of reported mutations\
Kyte-Doolittle hydrophobicity analysis (19 residues window) of human PIEZO1 prepared using the ProtScale program (Expasy). Triangles indicate the position of previously reported (green) and newly identified (red) mutations associated with DHS. Inset: Magnification of C-terminal region. Peaks with scores greater than 1.8 (red dashed line) indicate possible transmembrane regions.](nihms-470226-f0002){#F2}

![Recombinant hPIEZO1 channels with DHS-associated mutations display slow inactivation kinetics\
(**a**)Representative traces of mechanically activated inward currents recorded at −80 mV from HEK293T cells expressing either WT or indicated mutant hPIEZO1. Cells were stimulated by a series of mechanical steps (150 ms duration) in 1 μm increments. For each representative trace, the channel response corresponds to the indentation distance of the glass probe and is shown as a series of responses starting from the step which generates the first mechanically activated current(the initial steps that did not cause channel activation are not shown) till the step which generates the maximum response for that cell. The distance of the probe for the maximum response for each construct is indicated. (**b**) Representative WT (black) and mutant (colored) hPIEZO1 traces normalized to peak. Maximum current from each construct shown in panel (**a**) are overlaid to highlight difference in inactivation kinetics. Scale bar; 25 ms.(**c**) Average of inactivation time constant (tau, ms) for WT and mutant hPIEZO1 channels. Bars represent mean ± s.e.m. and numbers in parenthesis indicate number of cells tested for each condition. \* p\< 0.05, \*\*\* p \< 0.001; relative to WT hPIEZO1 (Student's t-test).](nihms-470226-f0003){#F3}

###### 

Clinical and haematological presentation of the 11 Index-Cases

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Id   Piezo1\    Age[\*](#TFN1){ref-type="table-fn"}   Family\   PHK   RBC\       Hb\      MCV\    MCCH\   Retic.\     PNE   Typical DHS ektacytometry\
       Mutation                                         History         (10^12^\   (g/dL)   (fL)    (%)     (10^9^/L)         (IDmax, Omin and\
                                                                        /L)                                                   O'mOsm/kg)
  ---- ---------- ------------------------------------- --------- ----- ---------- -------- ------- ------- ----------- ----- ----------------------------
  F1   A2020T     48                                    Y         Y     5.03       15.6     88.9    34      259         N     Y (0.41, 112, 325)

  K1   E2496ELE   16                                    N         N     3.09       10.3     102.8   32.5    136         N     Y (0.41, 100, 275)

  K2   E2496ELE   15                                    ND        ND    4.05       14.4     98.5    36      202         ND    Y (0.39, 135, 286)

  K3   E2496ELE   11                                    Y         ND    3.28       11.3     91.9    37.3    275         ND    Y (0.45, 119, 298)

  K4   R1358P     69                                    N         N     4.47       15.4     98.1    35.2    367         ND    Y (0.41, 123, 301)

  K5   E2496ELE   21                                    Y         ND    3.41       12.7     98.9    37.5    256         N     Y (0.45, 117, 288)

  K6   E2496ELE   18                                    Y         N     3.38       12.5     102.5   36      378         N     Y (0.48, 99, 278)

  K7   E2496ELE   42                                    Y         ND    3.19       12.6     108.6   36.5    290         ND    Y (0.50, 99, 283)

  K8   T2127M     65                                    Y         Y     5.21       17.2     88.4    37.3    151         ND    Y (0.47, 128, 340)

  F2   E2496ELE   30                                    Y         Y     ND         9.4      99.1    ND      182         Y     Y (0.42, 122, 303)

  F3   E2496ELE   26                                    Y         Y     3.39       13.9     120     33.8    220         Y     Y (0.47, 119, 317)
  --------------------------------------------------------------------------------------------------------------------------------------------------------

Age represents the age at diagnosis.

PHK: Pseudohyperkalaemia, RBC: red blood cells count, Hb: Haemoglobin, MCV: Mean Corpuscular Volume, MCCH: Mean corpuscular concentration of haemoglobin, Retic: reticulocytes count, PNE: Perinatal Edema. Typical DHS ektacytometry shows normal RBC deformability (IDmax) and decreased Omin and O' reflecting RBC dehydration. (Normal range: IDmax 0,38-0,55, 0min 135-155 mosm/kg, 0′ 340-375 mosm/kg).

###### 

Clinical and haematological comparison between index patients with PIEZO1 mutations

  --------------------------------------------------------------
                           E2496ELE\     Others\       p-value
                           (N=8)         (N=3)         
  ------------------------ ------------- ------------- ---------
  Age (years)              20.5\         60.6\         0.01
                           (11-42)       (48-69)       

  Reticulocytes\           256.2\        259\          0.9
  (n /mm3)                 (136-378)     (151-367)     

  Red Blood Cells Count\   3.4\          4.9\          0.007
  (10^12^ /L)              (3.09-4.05)   (4.47-5.21)   

  Hemoglobin (g/l)         12.3\         16.1\         0.002
                           (9.4-14.4)    (15.6-17.2)   

  Mean Cell Volume\        100.5\        91.8\         0.04
  (fL)                     (98.5-120)    (88.4-98.1)   

  Mean Corpuscular\        36\           35.5\         0.9
  Hemoglobin\              (32.5-37.5)   (34-37.3)     
  Concentration\                                       
  (%)                                                  
  --------------------------------------------------------------

Mean age at diagnosis and haematological parameters (including minimal and maximal values) between the eight index cases harbouring the recurrent mutationE2496ELE versus the three DHS index cases with other missense PIEZO1 mutations ("others").

###### 

Inactivation kinetics of hPIEZO1 mutations

  Mutation           Inactivation kinetics   I~max~at −80 mV                                                         
  ------------------ ----------------------- ----------------- ------------------------------------------------ ---- -----------
  hPIEZO1            25                      5.0 ± 0.3         8.6 ± 0.4                                        9    2.2 ± 0.4
  hPIEZO1-R1358P     12                      4.3 ± 0.5         13.8 ± 1.5[\*\*\*](#TFN7){ref-type="table-fn"}   12   1.4 ± 0.3
  hPIEZO1-A2020T     19                      4.7 ± 0.2         12.2 ± 0.5[\*\*\*](#TFN7){ref-type="table-fn"}   8    2 ± 0.4
  hPIEZO1-T2127M     10                      5.0 ± 0.5         11 ± 0.7[\*](#TFN6){ref-type="table-fn"}         10   2.2 ± 0.8
  hPIEZO1-M2225R     16                      4.4 ± 0.4         13.6 ± 1.1[\*\*\*](#TFN7){ref-type="table-fn"}   9    7.7 ± 3.7
  hPIEZO1-R2456H     14                      4.7 ± 0.4         22.2 ± 2.1[\*\*\*](#TFN7){ref-type="table-fn"}   7    1.6 ± 0.5
  hPIEZO1-E2496ELE   16                      4.2 ± 0.3         15 ± 1.1[\*\*\*](#TFN7){ref-type="table-fn"}     11   1.5 ± 0.2

All values measured from cells held at −80 mV membrane potential.

Average values expressed as mean ± s.e.m.

p\< 0.05;

p \< 0.001 relative to WT hPIEZO1 (Student's t-test).
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